Dichloromethylpyrazine | 40639-68-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: Dichloromethylpyrazine
• 英文别名: 2-(dichloromethyl)pyrazine
• CAS: 40639-68-7
• 化学式: C₅H₄Cl₂N₂
• 分子量: 163.006
• InChiKey: IUIDZOFNUPTVRQ-UHFFFAOYSA-N

物化性质

• 沸点：
  87-90 °C(Press: 10 Torr)
• 密度：
  1.408±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  Dichloromethylpyrazine 在 N-氯代丁二酰亚胺 作用下， 以 四氯化碳 为溶剂， 反应 6.0h， 生成 2-Dichloromethyl-3-chloropyrazine
  参考文献：
  名称：

  Synthesis of trichloromethyl-substituted azines from dichloromethyl-substituted azines and carbon tetrachloride under interphase catalysis conditions

  摘要：

  DOI：

  10.1007/bf00506846
• 作为产物：
  描述：

  2-甲基吡嗪 在 N-氯代丁二酰亚胺 、 过氧化氢苯甲酰 作用下， 以 四氯化碳 为溶剂， 生成 Dichloromethylpyrazine
  参考文献：
  名称：

  Synthesis of trichloromethyl-substituted azines from dichloromethyl-substituted azines and carbon tetrachloride under interphase catalysis conditions

  摘要：

  DOI：

  10.1007/bf00506846

文献信息

• [EN] ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] DÉRIVÉS FUSIONNÉS D'ACIDE CYCLOPENTANE-CARBOXYLIQUE À SUBSTITUTION ACYLAMINO, ET LEUR UTILISATION COMME PRODUITS PHARMACEUTIQUES
  申请人：SANOFI AVENTIS

  公开号：WO2009135590A1

  公开（公告）日：2009-11-12

  The present invention relates to compounds of the formula (I), wherein A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use and pharmaceutical compositions comprising them.

  本发明涉及具有式(I)的化合物，其中A，Y，Z，R3至R6，R20至R22和R50具有权利要求中指出的含义，它们是有价值的药物活性化合物。具体而言，它们是内皮分化基因受体2（Edg-2，EDG2）的抑制剂，该受体可被溶血磷脂酸（LPA）激活，也被称为LPA1受体，并且可用于治疗例如动脉粥样硬化、心肌梗死和心力衰竭等疾病。本发明还涉及制备式(I)化合物的方法、它们的使用以及包含它们的药物组合物。
• Keratinocyte growth inhibitors and hydroxamic acid derivatives
  申请人：——

  公开号：US20030229113A1

  公开（公告）日：2003-12-11

  This invention relates to a keratinocyte-proliferation inhibitor comprising as active ingredient a compound having an activity of inhibiting the solubilization of heparin-binding EGF-like growth factor bound to cell membranes and a compound of the formula (I); 1 or pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 are hydrogen atom or alkyl and X is substituted benzene or the like.

  本发明涉及一种角质形成细胞增殖抑制剂，其活性成分为具有抑制细胞膜结合肝素结合表皮生长因子样生长因子溶解活性的化合物，以及具有式(I)的化合物；1或其药学上可接受的盐，其中R1、R2、R3为氢原子或烷基，X为取代苯或类似物。
• Improved Halogenation of Methyl Aromatics and Methyl Heteroaromatics: Unexpected Reactivity of Tetrahalogeno-diphenylglycolurils
  作者：Florian Moretti、Guillaume Poisson、Alain Marsura

  DOI：10.1002/hc.21314

  日期：2016.5

  exploited in a new direction as reagents for free radical substitution toward some N-halosuccinimide nonreactive bis-heterocycles. An unexpected selectivity and reactivity were observed with methyl benzenes, methyl heterocycles, and methyl-bis-heterocycles of interest. A chemometric study has been performed to optimize five independent factors of the chlorination reaction with TCDGU. The predictive model

  1,3,4,6-四氯 (TCDGU) 和 1,3,4,6-四溴-3α,6α-二苯基甘脲平滑卤素氧化剂已被开发用作自由基取代某些 N-卤代琥珀酰亚胺非反应性试剂的新方向双杂环。对于感兴趣的甲基苯、甲基杂环和甲基双杂环，观察到了意想不到的选择性和反应性。已进行化学计量学研究以优化与 TCDGU 氯化反应的五个独立因素。建立了卤化转化率和一氯化比的预测模型。
• ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS
  申请人：SCHAEFER Matthias

  公开号：US20110152290A1

  公开（公告）日：2011-06-23

  The present invention relates to compounds of the formula I, wherein A, Y, Z, R 3 to R 6 , R 20 to R 22 and R 50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA 1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

  本发明涉及式I的化合物，其中A、Y、Z、R3至R6、R20至R22和R50具有所述权利要求中指示的含义，这些化合物是有价值的药物活性化合物。具体来说，它们是内皮分化基因受体2（Edg-2，EDG2）的抑制剂，该受体被溶血磷脂酸（LPA）激活，也称为LPA1受体，可用于治疗动脉粥样硬化、心肌梗塞和心力衰竭等疾病。本发明还涉及制备式I化合物的方法、它们的用途以及包含它们的药物组合物。
• Pyridazinoquinolinetriones as NMDA Glycine-Site Antagonists with Oral Antinociceptive Activity in a Model of Neuropathic Pain
  作者：Thomas M. Bare、Dean G. Brown、Carey L. Horchler、Megan Murphy、Rebecca A. Urbanek、Vernon Alford、Christine Barlaam、Martin C. Dyroff、James B. Empfield、Janet M. Forst、Keith J. Herzog、Richard A. Keith、Alan S. Kirschner、Chi-Ming C. Lee、Joseph Lewis、Frances M. McLaren、Kathy L. Neilson、Gary B. Steelman、Shephali Trivedi、Edward P. Vacek、Wenhua Xiao

  DOI：10.1021/jm060212s

  日期：2007.6.1

  A series of 7-chloro-2,3-dihydro-2-[1-(pyridinyl)alkyl]-pyridazino[4,5-b]quinoline-1,4,10(5H)-triones were synthesized and found to have potent activity at the glycine site of the NMDA receptor. In some cases, these compounds possessed poor aqueous solubility that may have contributed to poor rat oral bioavailability. Subsequently, compounds have been identified with improved aqueous solubility and oral bioavailability. Several of these compounds were examined in a rat chronic constrictive injury (CCI) model of neuropathic pain and found to have potent activity when dosed orally.